Randomized controlled trials (RCTs) are considered the gold standard for demonstrating the efficacy of a treatment or intervention; however, the RCT study design alone is insufficient to prevent all forms of bias. In this paper, we review conflicts of interest and other biases that pose challenges to the methodological rigor of psychedelic RCTs, and explore recommended bias mitigation measures....
Substance use disorders (SUDs) are notoriously difficult to treat due to complex biopsychosocial underpinnings and high relapse rates. Recent evidence positions ketamine-assisted psychotherapy (KAP) as a promising intervention for treatment-resistant addiction. This review explores ketamine’s neurobiological mechanisms, its synergistic effect with psychotherapy, and clinical data supporting its...
Objective: This study evaluates the feasibility and acceptability of delivering Mindful Self-Compassion (MSC) to veterans with moral injury and co-occurring PTSD and substance use disorder (PTSD-SUD). Methods: Veterans (N = 26; M age = 50.92; 100% male) were recruited for an 8-week MSC group. Participants completed measures of self-compassion, guilt, shame, PTSD, and substance use outcomes at...
Adults with alcohol use disorder who received two sessions of psilocybin‐assisted therapy demonstrated personality shifts toward normalization of abnormal trait expression, a secondary analysis of a randomized trial has found. A decrease in impulsiveness was found to be associated with reduced drinking post‐treatment, with the strongest effect for psilocybin‐treated individuals who had engaged...
According to ontological addiction theory, the root cause of mental suffering is a dysfunctional conceptualisation of the self. Typically, an individual with such a flawed self-concept deems themselves to be intrinsically separate from their surroundings, with their beliefs, choices and behaviours structured in order to reinforce their sense of an independently existing self. The Ontological...
Ketamine has demonstrated early promise for treating substance use disorder (SUD). Despite the emerging evidence for ketamine-based approaches for SUD, little has been published on the integration of ketamine-assisted psychotherapy (KAP) with existing pharmacologic, psychosocial, and peer-support approaches to treatment and recovery, including 12-step programs. Here, we present the case of a...
There has been substantial recent renewed interest and investment to assess the therapeutic potential of psychedelic compounds in addiction disorders. This editorial discusses the available evidence from randomised trials and future research directions in the field, together with potential implications for patients, professionals and the wider addiction treatment system.
Advances in Dual DiagnosisMarch 20, 2025Mohannad A. Aldiqs, Ayman M. Hamdan-Mansour, Afaf Nowwara et al.
This study aims to examine the effectiveness of a brief six-session version of the mindfulness-based cognitive intervention derived from the positive psychology approach to decrease the symptoms of anxiety among individuals diagnosed with substance use disorders (SUDs). An experimental research design with pre- and post-tests and a one-month follow-up were used. The study sample comprised 34...
Recent clinical trials on classic psychedelics for depression and anxiety have raised questions about their potential to treat other psychiatric conditions. Evidence from pre-clinical and clinical research suggests psychedelics may help with substance use disorders, with ongoing registered trials. Behavioral addictions, sharing features with substance addictions, may also respond to psychedelic...
Opioid use disorder (OUD) has reached epidemic proportions, with many countries facing high levels of opioid use and related fatalities. Although currently prescribed medications for OUD are considered lifesaving, they inadequately address negative affect and cognitive impairment, resulting in high relapse rates to nonmedical opioid use even years after drug cessation (protracted abstinence)....
This paper presents a novel information-theoretic proof demonstrating that the human brain as currently understood cannot function as a classical digital computer. Through systematic quantification of distinguishable conscious states and their historical dependencies, we establish that the minimum information required to specify a conscious state exceeds the physical information capacity of the...
This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic interventions. Patterns of misuse demonstrate the complex interplay of neurobiological, socio-economic, demographic and psychological factors with adolescents, women and polysubstance users identified as high-risk groups. Neurobiological findings...
Ketamine, a substance used for anesthesia and known for inducing dissociation, can lead to addiction and the development of severe withdrawal symptoms. Ketamine alters brain networks before affecting somesthetic sensation. Ketamine abuse was especially prevalent in East and Southeast Asia, and its popularity has continued to expand globally in recent decades. Ketamine is gaining popularity in...
Medications to treat substance use disorders (SUDs) remain suboptimal or, in the case of stimulants and cannabis, non-existent. Many factors have contributed to this paucity, including the biological complexity of addiction, regulatory challenges, and a historical lack of enthusiasm among pharmaceutical companies to commit resources to this disease space. Despite these headwinds, the recent...
Ketamine is an N-methyl D-aspartate (NMDA) receptor antagonist used to treat pain at subanesthetic doses. Ketamine is beneficial for pain control in patients who have a high tolerance to opioids and are experiencing opioid-induced hyperalgesia. This study characterizes oral ketamine use for analgesia at a large academic hospital and reports safety outcomes for hospitalized patients. This study...
Neurobiology of DiseaseMarch 1, 2025Liubov S. Kalinichenko, Iulia Zoicas, Anne-Marie Bienia et al.4 citations
Addiction is a chronic and severe mental disorder with high gender- and sex-specificity. However, the pathogenesis of this disorder is not fully elucidated, and no targeted pharmacotherapy is available. A growing body of evidence points out the potential involvement of the ceramide system in the pathophysiology of addiction. A pathogenic pathway for several mental disorders based on the...
Ketamine abuse damages brain function and structure, increasing reactive oxygen species and apoptosis in the cerebral cortex, but moderate-intensity continuous training (MICT) can enhance antioxidant defences and reduce apoptosis. Therefore, we aimed to answer whether MICT can reduce the side effects of chronic ketamine abuse. 24 Wistar rats were split into control (CON), ketamine abuse (KET),...
Background: Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects of a single dose have not been investigated. Aims: To investigate the pharmacokinetics, feasibility, safety and efficacy of single-dose psilocybin therapy in AUD. Methods: This...
BACKGROUND: The widespread availability and accessibility of over-the-counter (OTC) medicines play a vital role in modern healthcare systems, enabling individuals to manage minor health concerns independently. However, certain OTC medications possess pharmacological properties that render them susceptible to misuse and abuse, including stimulants, laxatives, sedatives, and opiate-containing...